The GAstric Precancerous Conditions Study (GAPS)
This study, called GAPS, is looking at changes in the stomach that can lead to stomach cancer. Stomach cancer is often found late, making it harder to treat. Researchers want to understand how conditions like atrophic gastritis and intestinal metaplasia (pre-cancerous changes in the stomach lining) progress or improve over time. You might be able to join if you are between 35 and 84 years old and are having an endoscopy (a procedure to look inside your stomach) for reasons like stomach pain, indigestion, or a family history of stomach cancer. The study will track changes in your stomach lining over at least 24 months to see if these conditions get better or worse, or if dysplasia (abnormal cell growth) develops.
- Study design
- This is an observational study, meaning researchers will watch participants over time without giving any specific treatments. It plans to enroll 600 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for at least 24 months to assess changes in their stomach conditions.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
The GAstric Precancerous Conditions Study
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Robert J Huang, MD · PRINCIPAL_INVESTIGATOR · Stanford University
- Joo Ha Hwang, MD, PhD · PRINCIPAL_INVESTIGATOR · Stanford University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Exclusion
What this trial measures
- Histologic Progression or Regression Assessed by OLGA Scoreat least 24 months after enrollment
Histologic progression or regression will be evaluated using the Operative Link on Gastritis Assessment (OLGA) score. This score stages the severity of atrophic gastritis based on histological findings.
- Histologic Progression or Regression Assessed by OLGIM Scoreat least 24 months after enrollment
Histologic progression or regression will be assessed using the Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) score. This score stages the extent of intestinal metaplasia.
- Development of Dysplasiaat least 24 months after enrollment
The presence or absence of dysplasia will be assessed as an indicator of histologic progression.
- Development of Carcinomaat least 24 months after enrollment
The presence or absence of carcinoma will be assessed to evaluate disease progression.